Bringing the Oncology Community Together
FDA Approves Bevacizumab for Recurrent Ovarian Cancer
The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.
Read More >>
New Research Focuses on Personalized Treatments in Ovarian Cancer
Safra Provides an Overview of PARP Inhibitors in Ovarian Cancer
Trebananib Misses Survival Goal in Phase III Ovarian Cancer Study
Promising Treatments on Horizon in Ovarian Cancer
New Method Explored for Personalized Vaccines for Ovarian Cancer
Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer
View More >>
- A Network of Your Peers
View more >>
Dr. Ledermann Discusses Olaparib in Ovarian Cancer
Dr. Halle Moore Discusses Results of the Phase III POEMS Study in Breast Cancer
Dr. Dowdy on the Association of Molecular Subtypes and Responses to Bevacizumab in Ovarian Cancer
Most Popular Right Now
Tweets by @OncLive
Support and Assistance for Patients with Cancer
Useful information on supporting and assisting patients with cancer.
Community Practice Connections: 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies
CME activity worth 1.0 CME credits led by James Tate Thigpen, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.